RxDoctor Payments DataLook up a doctor →

Cindy Chang

Family · Tucson, AZNPI 1316561236

Payments from drug & device makers

$14,203in general payments, 2019–2025

Across 678 payments — averaging $20.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Johnson & Johnson$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Bristol Myers Squibb$735
  • Takeda Pharmaceuticals U.S.A., Inc.$707
  • Nestle Healthcare Nutrition Inc.$608
  • plus $5K from 31 others

What the payments were for

  • Food & beverage$14,06199%
  • Education$1421%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,203 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$47,177
Medicare patients
373
Services billed
541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase53$230,536
OcalivaObeticholic Acid16$148,283
CreonLipase/Protease/Amylase44$134,857
LinzessLinaclotide47$50,103
MotegrityPrucalopride Succinate31$16,608
TrulancePlecanatide23$16,417
Mesalamine29$10,362
Dexlansoprazole DrDexlansoprazole37$8,349
Famotidine335$5,496
ClenpiqSod Picosulf/Mag Ox/Citric Ac29$5,018
Omeprazole256$4,719
Lubiprostone32$4,496
Pantoprazole Sodium353$4,102
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates64$3,855
Sucralfate115$2,709

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$586$230,53653 claims
AbbVieCreon, Linzess$4,309$184,96091 claims
Intercept Pharmaceuticals, Inc.Ocaliva$446$148,28316 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$707$16,60831 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$1,091$16,41723 claims
Ferring Pharmaceuticals Inc.Clenpiq$132$5,01829 claims
Braintree Laboratories, Inc.Suflave$106$2,54220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.

Other family in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →